Millennium Management
ADCT icon

Millennium Management’s ADC Therapeutics ADCT Stock Holding History

Millennium Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$506K Buy
+135,000
New +$532K ﹤0.01% 4763
2024
Q3 		– Sell
-100,000
Closed -$316K – 6041
2024
Q2 		$316K Buy
+100,000
New +$397K ﹤0.01% 4881

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's ADCT Position: Q1 2026 in Review

Millennium Management increased its ADC Therapeutics (ADCT) stake by 850% in Q1 2026, buying an estimated $11M and bringing the position to 3,119,154 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Millennium Management first reported a position in ADCT in Q2 2020 and has held it in 20 quarters since. The position peaked at $13.1M in Q4 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Millennium Management held 3,119,154 shares of ADC Therapeutics worth $11.7M as of Q1 2026.
  • Millennium Management bought 2,790,725 ADC Therapeutics shares in Q1 2026, an estimated $11M.
  • ADC Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2029 holding.
  • Millennium Management first reported a position in ADC Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • Millennium Management's ADC Therapeutics position peaked at $13.1M in Q4 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.